Elekta AB (publ)
STO:EKTA B
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
60.3
87.5
|
| Price Target |
|
We'll email you a reminder when the closing price reaches SEK.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Elekta AB (publ)
Elekta AB (publ)
Revenue
Elekta AB (publ)
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Elekta AB (publ)
STO:EKTA B
|
Revenue
kr18.1B
|
CAGR 3-Years
10%
|
CAGR 5-Years
6%
|
CAGR 10-Years
N/A
|
|
|
S
|
Surgical Science Sweden AB
STO:SUS
|
Revenue
kr859.8m
|
CAGR 3-Years
60%
|
CAGR 5-Years
58%
|
CAGR 10-Years
N/A
|
|
|
CellaVision AB
STO:CEVI
|
Revenue
kr737.2m
|
CAGR 3-Years
11%
|
CAGR 5-Years
12%
|
CAGR 10-Years
13%
|
|
|
Getinge AB
STO:GETI B
|
Revenue
kr31.8B
|
CAGR 3-Years
2%
|
CAGR 5-Years
6%
|
CAGR 10-Years
N/A
|
|
|
Arjo AB (publ)
STO:ARJO B
|
Revenue
kr11B
|
CAGR 3-Years
7%
|
CAGR 5-Years
6%
|
CAGR 10-Years
N/A
|
|
|
Sedana Medical AB (publ)
STO:SEDANA
|
Revenue
kr174.1m
|
CAGR 3-Years
3%
|
CAGR 5-Years
21%
|
CAGR 10-Years
N/A
|
|
Elekta AB (publ)
Glance View
Elekta AB emanates sophistication and precision, standing at the forefront of medical technology. Established in 1972 by Lars Leksell, the Swedish innovator manifests a legacy deeply rooted in advancing oncology and neurosurgery treatment solutions. Elekta's forte lies in crafting state-of-the-art equipment and software that assist medical practitioners in treating complex cancers and brain disorders. Their products, such as the Leksell Gamma Knife and various advanced linear accelerators, showcase their commitment to minimally invasive treatment. By developing cutting-edge systems that refine radiation therapy and radio-surgery, Elekta plays a pivotal role in enhancing patient outcomes, offering more precise targeting of tumors with minimal damage to surrounding healthy tissues. Financially, Elekta thrives through a multi-faceted revenue model that harmoniously blends hardware sales with recurring income from maintenance services, software upgrades, and training. Their business strategy capitalizes on long-term relationships with healthcare providers, ensuring a steady demand for both product innovation and servicing their existing installations. By anchoring its revenue stream in this hybrid fashion, Elekta offers a compelling proposition for shareholders—a blend of resilient cash flow dynamics and growth through groundbreaking technological advancements. As the global healthcare landscape evolves, Elekta's continuous investment in research and development ensures they remain a venerated leader in tackling the world's challenges in cancer care and neurological disorders.
See Also
What is Elekta AB (publ)'s Revenue?
Revenue
18.1B
SEK
Based on the financial report for Apr 30, 2024, Elekta AB (publ)'s Revenue amounts to 18.1B SEK.
What is Elekta AB (publ)'s Revenue growth rate?
Revenue CAGR 5Y
6%
Over the last year, the Revenue growth was 7%. The average annual Revenue growth rates for Elekta AB (publ) have been 10% over the past three years , 6% over the past five years .
You don't have any saved screeners yet